About: Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.18 (-0.84%)
PALI NASDAQ Palisade Bio Inc
Palisade Bio Inc share price
Atividade de preço de PALI
Último preço
$ 1,180
Variação (24h)
-0,01 USD (0,84%)
Volume
3.12M
Volume (média 4 sem.)
-
Abertura
$ 1,20
Variação do dia
$ 1,15 - $ 1,25
Fechamento anterior
$ 1,19
Último negócio
29 Oct, 7:52 pm GMT+0
Atrasado
29 Oct, 7:52 pm GMT+0
PALI price performance
Atrasado
29 Oct, 7:52 pm GMT+0
quote.marketSignals